{"entity":{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","aka":[],"tldr":"First author of the phase 1/2 trial of India's first CAR-T therapy, which treated adults with relapsed lymphoma and leukaemia at six Indian centres.","summary":"Hasmukh Jain is a haematolymphoid medical oncologist at Tata Memorial Hospital and first author of the Lancet Haematology report of talicabtagene autoleucel (NexCAR19) in relapsed or refractory B-cell malignancies: 64 patients were enrolled across phase 1 and 2 at six tertiary centres, with an overall response rate of 73% in 51 evaluable patients and two treatment-related deaths. He runs lymphoma and CAR-T programmes at Tata Memorial and is an investigator on Indian and international lymphoma trials.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jain%20H%5BAuthor%5D%20Tata%20Memorial%20lymphoma%20CAR"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["talicabtagene-autoleucel"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":["talicel-phase-1-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-jain-talicabtagene-lancet-haem-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology (adult haematolymphoid), Tata Memorial Hospital","institutionId":"tata-memorial","specialisms":["Lymphoma","Acute leukaemia","CAR-T cell therapy","Clinical trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jain%20H%5BAuthor%5D%20Tata%20Memorial%20lymphoma%20CAR"}],"papers":[{"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study","journal":"Lancet Haematology","year":2025,"doi":"10.1016/S2352-3026(24)00377-6"}]},"route":"/people/jain-hasmukh/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/"}],"institution":[{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"trial":[{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/"}],"paper":[{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/"}],"company":[{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/"}]}}